Rachel Abbott
CEO Pan Cancer T
Seminars
Wednesday 16th September 2026
Next-Generation TCR Engineering: Integrating Co-Stimulation & Novel Antigen Targeting to Expand the Reach of T-Cell Therapies
11:15 am
- Engineering next generation TCR constructs with built in co-stimulatory signaling to deliver dual functionality through a single molecule
- Reducing reliance on additional receptors, knockouts, or complex modifications to improve manufacturability and clinical durability
- Targeting novel solid tumor antigens such as ROPN1 in triple negative breast cancer to address high unmet need and expand the reach of T-cell therapies into new indications
